Industries > Pharma > 3D Cell Culture and 3D Bioprinting Market Report 2022-2032

3D Cell Culture and 3D Bioprinting Market Report 2022-2032

Forecasts by Technology (Scaffold-Based, Scaffold-Free, Microfluidics-based, Magnetic Levitation, 3D Bioprinting, Others), by Application (Cancer and Stem Cell Research, Drug Discovery and Toxicology Testing, Tissue Engineering and Regenerative Medicine), by End-user (Pharmaceutical & Biotechnology Companies, Academic Institutes, Research Laboratories, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 15 February 2022
PAGES: 382
PRODUCT CODE: PHA1080
SUBMARKET: Biotechnology

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1080 Categories: , Tags: , ,

The global 3D Cell Culture & 3D Bioprinting market was valued at US$ xx bn in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2022-2032. The rising demand for new drugs development, 3D bioprinting for organ transplanting, rising stem cell research is a major driver propelling the market growth. Growing use of 3D cell culture model in cancer research, 3D bioprinting for drug discovery and development in pharmaceutics, 3D bioprinting for animal-free meat emerging economies are some of the major factors that boost the Global 3D Cell Culture & 3D Bioprinting Market.

How has COVID-19 had a significant negative impact on the 3D Cell Culture & 3D Bioprinting Market?
The COVID-19 pandemic has a significant negative impact on the 3D cell culture & 3D bioprinting market globally. The COVID-19 outbreak in 2020 led to international border controls, country-wide lockdowns, pharmaceutical manufacturing restrictions & limitations. This pandemic has hampered the production and distribution of 3D Cell Culture & 3D bioprinting technologies.

COVID-19 would undoubtedly have an effect on chronic and infectious diseases patients and their care for the near future. Creating support networks for physicians and patients will help to break down walls and provide patients with appropriate access to potentially life-saving services.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

How this Report Will Benefit you?
Visiongain’s 380+ page report provides 356 tables and 352 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global 3D cell culture & 3D bioprinting market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for 3D cell culture & 3D bioprinting. Get the financial analysis of the overall market and different segments including technology, application, and end-user, and capture higher market share. We believe that high opportunity remains in this fast-growing tissue engineering and regenerative medicine market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

CTA

What are the current market drivers?

Rising Development for New Drug Development
Rise in demand for drug development is expected to propel the demand for 3D cell culture & 3D bioprinting. According to the WHO, the prevalence of chronic illness cases is expected to increase by 57%, with higher illness cases in low- & middle-income nations. Additionally, the outbreak of pandemics in the current & past such as COVID19, SARS, Ebola, MERS, and H1N1 have added to the upsurge in drug development and vaccination.

Rising Stem Cell Research and 3D Bioprinting for Organ Transplanting
3D bioprinting for organ transplant, rising stem cell research and use of 3D cell culture model in cancer research is further driving the market adoption. Pharmaceutical companies like Corning Inc., Thermo Fisher Scientific Inc., Merck Group, and Lonza Group are constantly investing in 3D cell culture & 3D bioprinting to enhance the market growth. Also, the rising number of patients with chronic diseases along with growing healthcare awareness is projected to boost the demand for 3D cell culture & 3D bioprinting.

Where are the market opportunities?

Developing Biocompatible and Printable Biomaterials
The day-to-day increased demand in the medical field for the bio alternatives that could be able to perform the living activities of bodily organs has raised the interest of the researchers to design novel biomaterials. So, market leaders are drifting from conventional techniques to the innovative and enhanced techniques, thereby developing the biocompatible and printable biomaterials.

3D Bioprinting for Animal-Free Meat
Organoids developed from pluripotent stem cells or adult stem cells are three-dimensional cell cultures possessing certain key characteristics of their organ counterparts, and they can mimic certain biological developmental processes of organs in vitro. Therefore, they have promising applications in drug screening, disease modeling, and regenerative repair of tissues and organs. The combination of bioprinting and organoids with a focus on structure and function can facilitate further development of real organs.

3D Cell Culture and 3D Bioprinting Market Report 2022-2032
Need industry data? Please contact us today.

Competitive Landscape
The major players operating in the inflammatory bowel disease drugs market are Corning Inc., Thermi Fisher Scientific Inc., Merck Group, Lonza Group AG, Reprocell Inc., Organovo Inc., Cellink, Aspect Biosystems, EnvisionTEC, and Cyfuse Biomedical K.K.

These leading players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new drugs launch. For instance, October 2020, Merck collaborated with D1Med, a Shanghai-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today 3D Cell Culture and 3D Bioprinting Market Report 2022-2032: Forecasts by Technology (Scaffold-Based, Scaffold-Free, Microfluidics-based, Magnetic Levitation, 3D Bioprinting, Others), by Application (Cancer and Stem Cell Research, Drug Discovery and Toxicology Testing, Tissue Engineering and Regenerative Medicine), by End-user (Pharmaceutical & Biotechnology Companies, Academic Institutes, Research Laboratories, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for 3D Cell Culture and 3D Bioprinting Market Report 2022-2032

    Download sample pages

    Complete the form below to download your free sample pages for 3D Cell Culture and 3D Bioprinting Market Report 2022-2032

      Latest Pharma news

      Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

      The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

      23 April 2024

      READ

      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ

      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ